Alto Neuroscience Q2 2026: $27.6M Net Loss, CFO Adopts 10b5-1 Plan
ANRO has more than doubled off its 52-week low of $3.02.
Summary
Alto Neuroscience's Q2 2026 10-Q shows a widening net loss to $27.6 million, a strong cash position of $244.2 million, and a new CFO 10b5-1 trading plan.
Key Events · Earnings and Guidance · ANRO
-
Q2 Net Loss Widens to $27.6M
Net loss increased 56% year-over-year from $17.7M to $27.6M, driven by a $9.0M increase in R&D expenses, primarily for the ALTO-207 Phase 2b trial.
-
Cash Runway Extended
Cash and equivalents totaled $244.2M at June 30, 2026, plus $94.6M net proceeds from the July 2026 offering, funding operations for at least 12 months.
-
CFO Adopts 10b5-1 Trading Plan
CFO Nicholas Smith adopted a Rule 10b5-1 plan on June 30, 2026 to sell up to 134,886 shares over the next year, subject to price thresholds.
-
Securities Class Action Dismissed
On August 7, 2026, the court granted the company's motion to dismiss the IPO-related securities class action, with plaintiffs granted leave to file a third amended complaint.
Analysis · ANRO · Life Sciences
Alto Neuroscience reported a $27.6 million net loss for Q2 2026, up from $17.7 million a year earlier, driven by a 68% jump in R&D spending as the company advances its ALTO-207 program. The company ended the quarter with $244.2 million in cash and raised an additional $94.6 million in July, extending its runway. Separately, CFO Nicholas Smith adopted a Rule 10b5-1 trading plan for up to 134,886 shares, a routine but notable insider sale arrangement. The securities class action was dismissed on August 7, 2026, though plaintiffs may amend.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ANRO was trading at $28.50 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $3.02 to $29.70. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.